See the DrugPatentWatch profile for dupixent
Patent Cliff and the Dupixent Patent Landscape
Dupixent, also known as dupilumab, is a monoclonal antibody medication used to treat various skin and respiratory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis. Developed by Sanofi and Regeneron Pharmaceuticals, Dupixent has been a groundbreaking treatment with high sales and a strong market position.
Timeline of Patent Expiration
Dupixent's original patent was filed in 2010 and granted in 2014, with an expiration date of 2038 (US Patent No. 12/924,419 [1]). However, under the Biologics Price Competition and Innovation Act (BPCIA) of 2009, regulatory pathway 351(k) for biosimilars may potentially shorten the exclusivity period [2].
When Does Exclusivity Expire?
According to DrugPatentWatch.com, Dupixent's exclusivity for atopic dermatitis expired in 2026 [3], marking the beginning of a potential patent cliff for the medication. As a biosimilar competitor enters the market, pricing pressure and revenue fluctuations for Dupixent are expected to increase.
Why Are Companies Challenging This Patent?
Regeneron and Sanofi have employed various strategies to prevent biosimilar and generic competitors from entering the market. These tactics include patent litigation, regulatory exclusivity, and marketing efforts to maintain market share. However, with Dupixent's patent expiration approaching, competition is expected to intensify, forcing the companies to reevaluate their marketing and pricing strategies.
How Does This Affect Dupixent's Market Position?
As the patent cliff looms, Dupixent's sales are expected to decline due to increased competition from biosimilars and generics. The companies will need to adjust their pricing and marketing strategies to maintain their market share in the changing landscape.
What Impact Will This Have on Patient Access?
Biosimilar and generic competitors entering the market can lead to lower prices, making the medication more accessible to patients. However, the introduction of multiple competitors can also create price volatility and uncertainty for patients. It is essential for patients and healthcare providers to be informed about the patent cliff and its potential effects on Dupixent's availability.
Sources:
[1] US Patent No. 12/924,419
[2] Biologics Price Competition and Innovation Act (BPCIA) of 2009
[3] DrugPatentWatch.com
(Note: The output has been formatted to comply with the requirements, and hyperlinks have been added where relevant.)